We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

118 hedge funds and large institutions have $715M invested in Stoke Therapeutics in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 19

4% more funds holding

Funds holding: 114 → 118 (+4)

8% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 36

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7.05% less ownership

Funds ownership: 117.62% → 110.57% (-7%)

14% less capital invested

Capital invested by funds: $828M → $715M (-$113M)

80% less call options, than puts

Call options by funds: $94K | Put options by funds: $475K

Holders
118
Holders Change
+4
Holders Change %
+3.51%
% of All Funds
1.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
23
Increased
39
Reduced
36
Closed
19
Calls
$94K
Puts
$475K
Net Calls
-$381K
Net Calls Change
-$492K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$10.3M
2
Marshall Wace
Marshall Wace
United Kingdom
+$7.22M
3
MB
MPM BioImpact
Massachusetts
+$6.79M
4
Deutsche Bank
Deutsche Bank
Germany
+$6.32M
5
RI
RTW Investments
New York
+$6.05M

Top Sellers

Rank Fund Capital Flow
1
ST
Skorpios Trust
Cyprus
-$27.4M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$18.7M
3
Franklin Resources
Franklin Resources
California
-$16.9M
4
LGM
Logos Global Management
California
-$14.2M
5
Invesco
Invesco
Georgia
-$5.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Exome Asset Management
New York
$2.17M +$2.5M +176,600 New
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$2.1M +$485K +34,236 +25%
TI
28
Trexquant Investment
Connecticut
$1.99M -$253K -17,864 -10%
CC
29
Checkpoint Capital
California
$1.94M +$2.23M +157,514 New
Wellington Management Group
30
Wellington Management Group
Massachusetts
$1.68M -$94.4K -6,661 -5%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$1.65M +$1.76M +123,914 +1,212%
PAI
32
Palo Alto Investors
California
$1.55M – – –
Bank of America
33
Bank of America
North Carolina
$1.53M +$380K +26,850 +27%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$1.51M -$1.06M -75,131 -38%
Two Sigma Investments
35
Two Sigma Investments
New York
$1.43M +$25.1K +1,773 +2%
Squarepoint
36
Squarepoint
New York
$1.38M +$1.38M +97,625 +649%
N
37
Nuveen
North Carolina
$1.33M -$1.12M -79,264 -42%
Los Angeles Capital Management
38
Los Angeles Capital Management
California
$1.27M +$513K +36,240 +54%
Group One Trading
39
Group One Trading
Illinois
$1.25M +$1.44M +101,774 New
ECM
40
Element Capital Management
New York
$1.18M +$1.37M +96,380 New
WP
41
Woodline Partners
California
$1.16M -$82.2K -5,800 -6%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.13M -$340K -24,027 -21%
GGHC
43
Gilder Gagnon Howe & Co
New York
$1.12M +$30.9K +2,178 +2%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$1.02M +$41.1K +2,903 +4%
Barclays
45
Barclays
United Kingdom
$980K +$669K +47,239 +145%
UBS Group
46
UBS Group
Switzerland
$962K -$566K -39,942 -34%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$936K +$1.01M +71,647 +1,590%
FPCP
48
Fort Point Capital Partners
California
$927K – – –
AQR Capital Management
49
AQR Capital Management
Connecticut
$923K +$1.06M +75,089 New
Swiss National Bank
50
Swiss National Bank
Switzerland
$687K -$149K -10,500 -16%
1
2
3 4 5

STOK Hedge Fund Activity: Q3 2024 in Review

118 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2024, worth a combined $715M — down 14% from $828M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new STOK positions and 19 closed out — a net gain of 4 holders — while 39 added to existing stakes and 36 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $10.3M. The largest seller was Skorpios Trust, cutting an estimated $27.4M.

  • 118 institutional investors held Stoke Therapeutics (STOK) as of Q3 2024, up from 114 in Q2 2024.
  • Funds reported $715M of Stoke Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
  • 23 funds opened new Stoke Therapeutics positions in Q3 2024 and 19 closed out, a net change of +4 holders.
  • The largest Stoke Therapeutics buyer in Q3 2024 was Morgan Stanley, an estimated $10.3M added.
  • The largest Stoke Therapeutics seller in Q3 2024 was Skorpios Trust, an estimated $27.4M sold.

Based on aggregated 13F filings for Q3 2024.